DeSantis planning second Florida immigration detention facility
DeSantis said the Baker Correctional Institution, a state prison about 43 miles west of downtown Jacksonville, Fla., will now hold migrants awaiting deportation, according to The Associated Press. The move comes just weeks after the state opened its 'Alligator Alcatraz' facility in the Everglades.
Its construction was spurred by President Trump's crackdown on illegal immigration. Trump, along with Department of Homeland Security (DHS) Secretary Kristi Noem, visited the center last month.
'There is a demand for this. I'm confident that it will be filled,' DeSantis said in his announcement Thursday, referring to the new center as 'Deportation Depot.'
Development of the new facility could cost up to $6 million, despite the preexisting structure, he added. It currently features 1,300 beds but officials in the state are looking to add at least 700 more.
The proposal comes as federal judges weigh legal challenges to 'Alligator Alcatraz,' including whether a government agency or private contractor has the legal authority to detain people or act as an immigration enforcement officer and if its construction complies with federal environmental laws.
Last month, the governor said he hoped Florida would be used as the 'force multiplier' for deportations.
'I don't want it to be where illegals are just stored there, and then just kind of sitting. I want it to be where illegals are here, there's an aggressive processing and an aggressive deportation schedule,' he said.
The Trump administration has also been in contact with other GOP governors about similar construction projects in other states, according to Noem. While a list of potential states has not been provided, DHS announced a partnership with Indiana to build the ' Speedway Slammer,' a facility that would be located about 65 miles north of Indianapolis.
The Federal Emergency Management Agency (FEMA) just last month launched grant program that will offer funding to states to build detention centers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
6 minutes ago
- Washington Post
Meet the actor with Down syndrome who wants to run for president of Chile
SANTIAGO, Chile — Sebastián Solorza is already a familiar face to many Chileans, having starred in a popular Netflix series and won national acting awards. Now, the 43-year-old actor with Down syndrome wants to enter the race for president in Chile's national election this year. Solorza is racing against the clock to gather 35,000 signatures by Aug. 18, a requirement for him to run as an independent candidate. He positions himself as a 'point of balance' between the far right and the far left — a fierce ideological battle that dominates Chile's political scene . 'I listen with my heart,' Solorza told The Associated Press, adding that his condition allows him to offer a softer communication style. Should he enter the electoral race, his platform will focus on greater inclusion, improved healthcare and education, and enhanced security — a main concern of citizens who have been grappling with an unprecedented crisis of violence in recent years. Chile will choose its new president on Nov. 16, with the campaign so far defined by the mutual attacks between the two main contestants: The far-right José Antonio Kast, who lost to current leftist president Gabriel Boric in 2021, and Jeannette Jara, the ruling coalition's communist nominee . With three months remaining until the election, polls show Kast and Jara vying for the top two spots. This scenario suggests they would face each other in a second-round runoff on Dec. 14. Solorza argues that his candidacy offers a middle ground between political extremes, while working toward a 'more inclusive country.' 'I've spent my entire life breaking down prejudices, as an actor, as a worker and as a citizen,' he said last month when announcing his plans to run as an independent candidate. 'We all deserve the same opportunities.' The actor hopes his candidacy will give greater visibility to people with Down syndrome and other disabilities. While it's unlikely he will secure the necessary support to run for president — he has collected a little over 600 of the 35,000 signatures required — he sees his political foray as a success. Solorza keeps a tight schedule, balancing an acting career with a day job at a construction company. In his limited free time, he spends time visiting Congress, talking with members of the Parliament and meeting with constituents to promote his campaign. On the streets of Huechuraba, a quiet and green neighborhood in the northern part of Chile's capital, Solorza is often greeted by supporters, fans, and workers from restaurants and cafés where he is a regular. Always smiling, he walks slowly, making time for anyone who wants a photo or a brief chat. In Valparaíso — a coastal town about 100 kilometers (62 miles) from Santiago, where the Congress is based — Chileans show up to the Parliament to express their support. 'Good luck with the signatures,' one supporter said last week. 'Let it be the people who ultimately decide our future.' Solorza's political aspirations open the door to 'raise the voices of people with Down syndrome' and help to 'demystify myths and prejudices still present in society,' said Carolina Gallardo, director of the Chilean nonprofit Down Up Foundation, which offers support and community for families raising children with Down syndrome. The attempt at a political debut is just the latest in a long line of barriers Solorza has overcome. He was born and raised in the 1980s, a time with far less knowledge about Down syndrome than today . His mother, Jenny Solorza, recalls his early years as 'very dark,' because doctors never provided a clear diagnosis for their son, leading them to search for information on their own. 'We wanted to do our best and always encouraged him with music,' she said. As a result, 'Sebastián has a very broad musical culture, and that's what he grew up with.' Solorza attended special schools where he developed his passion for the arts, fueled by music, rather than focusing on traditional academics. At 18, he received a scholarship to join a theater school and began performing regularly on stage and appearing in popular TV talk shows. He later rose to national fame for his leading role as Tomy in the Chilean thriller 'Chromosome 21.' The series, which follows a detective trying to determine if a young man found at a murder scene is a witness or a suspect, ranked second on Netflix in Chile just two days after its release in 2022. The part earned Solorza the Best New Actor award at the 2023 Caleuche Awards, one of the most important ceremonies in the Chilean film industry. Despite social media criticism that he lacks preparedness and political experience to run for office, he insists he will not be deterred. 'I know my candidacy would be uncomfortable for many,' he said. 'But I am here to support minorities.' ____ Follow AP's coverage of Latin America and the Caribbean at
New York Times
6 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
New York Post
36 minutes ago
- New York Post
Ukrainian sniper breaks world record with 13,000-foot kill shot against Russian forces: report
A Ukrainian sniper unit on Thursday reportedly broke the world record for the longest confirmed sniper kill, eliminating Russian troops from a distance of more than 13,000 feet. The shot, fired by a Ukrainian-produced rifle and aided by artificial intelligence and drone guidance, left two Russian soldiers dead in the area of Pokrovsk, Ukraine, the Kyiv Post reported. 'The record-breaking shot was made on Aug. 14, 2025, using artificial intelligence under the guidance of [an unmanned aerial vehicle] complex with a 14.5 mm alligator rifle,' said military journalist Yuri Butusov, according to the Kyiv Post. The shooting took place amid increased Russian attacks in the area surrounding Pokrovsk, which was once a city with more than 60,000 residents, the Post reported. The previous world record belonged to a 58-year-old Ukrainian sniper who eliminated a target from a distance of around 12,400 feet, the outlet added. The record-breaking shot reportedly took place a day before President Donald Trump's closely-watched summit Friday with Russian President Vladimir Putin. 3 A Ukrainian soldier in the sniper unit of the 108th Territorial Defense Brigade readies a rifle during training on Nov. 4, 2023. Anadolu via Getty Images 3 The previous world record was held by another Ukrainian sniper who took out a Russian soldier from nearly 2½ miles away with a high-tech rifle known as 'Horizon's Lord.' SBU 3 Ukrainian soldiers take part in a sniper shooting exercise at a training facility outside Kyiv on Nov. 21, 2023. AFP via Getty Images Putin, who spoke first in a joint press conference held by the two world leaders, described the talks as a 'constructive atmosphere of mutual respect.' Ukrainian President Volodymyr Zelensky is scheduled to meet with Trump in Washington, DC, Monday. Zelensky said in a post on X that he and Trump will 'discuss all of the details regarding ending the killing and the war.'
